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CORRESPONDENCE
guidelines. Concomitant aspirin was
given more frequently to ximelagatran-
treated patients (337; 20%), than
warfarin-treated patients (290; 17%) in
the SPORTIF III trial (p=0·042). 
By way of reassurance as to the
validity and robustness of the
conclusion of non-inferiority between
the groups, however, the results
between treatment groups are
consistent, irrespective of aspirin use.
The estimated difference, with 95%
CIs, between treatment for non-users of
aspirin was similar to the overall results.
Overall, 40 events occurred in the
ximelagatran group during 2446
patient-years, a yearly rate of 1·64%,
compared with 56 in the warfarin group
during 2440 patient-years, a yearly rate
of 2·29%, yielding a difference of
–0·66% (95% CI –1·45 to 0·13). For
patients receiving concomitant aspirin
during the trial, 14 events occurred
during 477 patient-years (2·94%) in the
ximelagatran group versus 16 events
during 399 patient-years (4·01%) for
the warfarin group, a difference of
–1·08% (–3·57 to 1·42). The
corresponding results for patients not
receiving concomitant aspirin during
the trial were 26 events during 1969
patient-years (1·32% per year) for the
ximelagatran group versus 40 events
during 2042 patient-years (1·96% per
year) in the warfarin group, a difference
of –0·64% (–1·43 to 0·15). The test for
an interaction between the study drug
and concomitant aspirin use resulted in
a p value of 0.85.
The SPORTIF Executive Steering
Committee acknowledge the potential
implication of these data, which are
being considered fully in association
with the results from the sister trial,
SPORTIF V (which was identical in
design except for being double-blind),
as is the full preplanned pooled analysis
of the results from both trials. These
data could provide additional insights
into any potential imbalance of aspirin
use between the groups. However, we
cannot divulge these data before their
full peer review and subsequent
publication. In addition, a secondary
manuscript focusing specifically on the
topic of aspirin use in the SPORTIF
trials is being considered by an
authoring group for publication after
both SPORTIF studies have been
published in full. 
I have served as a consultant and received
payment from AstraZeneca to attend meetings
related to the trial, and for travel expenses,
speaking engagements, or research.
S Bertil Olsson, on behalf of the SPORTIF
III and V Executive Steering Committee
Department of Cardiology, University Hospital,
Lund SE-221 85, Sweden
(e-mail: bertil.olsson@kard.lu.se)
Aspirin bias in SPORTIF III
trial
Sir—The results of the open-label
SPORTIF III trial (Nov 22, p 1691)1
could have been biased by the uneven
distribution of recipients of aspirin
treatment after randomisation. The
authors claim that aspirin was given to
patients enrolled in the trial, as per
present guidelines for treatment of
concomitant coronary atherosclerotic
disease, which is acceptable.2
However, the randomisation clearly
indicates that the proportion of
patients with coronary atherosclerotic
disease is equal in both treatment
groups—ie, 40% each.3 Significantly
more people received post-
randomisation aspirin treatment in the
ximelagatran group than in the
warfarin group. A reason for this
difference has not been provided to
the extent that it would not invalidate
the results. Was the observed non-
inferiority due to bias by concurrent
aspirin treatment, which was more
common in the ximelagatran
treatment group? Was this bias
introduced by treating physicians,
since it was an open-label trial?
Murali Karthick Vadivelu
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Author’s reply
Sir—Murali Karthick Vadivelu raises
an important question regarding
differences in the use of aspirin by
patients in the two treatment groups of
the SPORTIF III trial, and suggests
that this could potentially have been
owing to bias resulting from the open-
label design of the trial. Concurrent
aspirin use of up to 100 mg per
day was allowed for patients with
associated coronary atherosclerotic
disease, at the discretion of treating
physicians, in both the SPORTIF III
and SPORTIF V trials, as
recommended by current practice
Convergence of
atherosclerosis and
Alzheimer’s disease
Sir—In their Review on dementias,
Ivan Casserly and Eric Topol (Apr 3,
p 1139)1 include many details (some of
them factual, other ones mainly
speculative) on the pathogenetic links
between vascular and degenerative
dementias. In that regard we were
rather surprised that they missed a
reference to the prestigious Medical
Research Council Cognitive Function
and Aging Study.2
Even more surprising was the finding
that the authors managed to avoid the
term “hypertension” throughout their
text, thereby letting go of a vast body of
literature on hypertension as a key
factor in both vascular dementia and
Alzheimer’s disease.3,4 They mention
the word just once, hidden in a panel
and referring to a single study,5 which,
although covering hypertension, did
not carry the word in its title.
We cannot help wondering why the
authors, who otherwise present so many
tiny details in their text, saw fit to
lump such a distinctive disorder as
hypertension together with other
vascular conditions under the vague
cover of “vascular” risk factors. In our
view such a camouflage totally under-
mines their attempt to develop a fresh
and distinctive paradigm. From a prag-
matic point of view they also bear the
responsibility of having done a disservice
to one of the few proven prophylactic
angles4 in the uphill battle against the
rising incidence of dementias.
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